减毒活流感疫苗在哮喘儿童中的安全性
该研究纳入151名5至17岁哮喘儿童,随机分配接受四价减毒活流感疫苗(LAIV4)或四价灭活流感疫苗(IIV4),比较接种后42天内哮喘急性发作比例。结果显示LAIV4组哮喘急性发作比例为11%(8/74),IIV4组为15%(10/68),达到非劣效界值,且两组哮喘症状频率、呼气峰流速(PEFR)变化及哮喘控制测试评分无显著差异。
要点
- LAIV4在5至17岁哮喘儿童中未增加哮喘急性发作频率。
- LAIV4组与IIV4组哮喘症状、PEFR变化及控制测试评分无显著差异。
核心结论
- 在5至17岁哮喘儿童中,LAIV4与IIV4相比未增加哮喘急性发作频率、哮喘相关症状或PEFR下降。
研究设计与样本
- 随机对照试验,纳入151名5至17岁哮喘儿童,按1:1随机分配接受IIV4或LAIV4,接种后监测42天。
- 符合方案分析纳入142名参与者。
主要发现
- 接种后42天内,142名参与者中18名(13%)发生哮喘急性发作,LAIV4组8/74(11%),IIV4组10/68(15%),LAIV4-IIV4差异为-0.0390(90% CI -0.1453至0.0674),达到非劣效界值。
- 调整哮喘严重程度后,LAIV4仍非劣效于IIV4。
- 接种后14天内,两组哮喘症状频率、PEFR变化及儿童哮喘控制测试/哮喘控制测试评分无显著差异。
关键数值与推荐
- 非劣效界值:LAIV4-IIV4差异的90% CI下限大于预设界值(原文未报告具体界值)。
临床怎么用
- 对于5至17岁哮喘儿童,LAIV4可作为与IIV4同样安全的选择,不增加哮喘急性发作风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma, comparing the proportion of children with asthma exacerbations after LAIV4 or quadrivalent inactivated influenza vaccine (IIV4). METHODS: We enrolled 151 children with asthma, aged 5 to 17 years, during 2 influenza seasons. Participants were randomly assigned 1:1 to receive IIV4 or LAIV4 and monitored for asthma symptoms, exacerbations, changes in peak expiratory flow rate (PEFR), and changes in the asthma control test for 42 days after vaccination. RESULTS: We included 142 participants in the per-protocol analysis. Within 42 days postvaccination, 18 of 142 (13%) experienced an asthma exacerbation: 8 of 74 (11%) in the LAIV4 group versus 10 of 68 (15%) in the IIV4 group (LAIV4-IIV4 = -0.0390 [90% confidence interval -0.1453 to 0.0674]), meeting the bounds for noninferiority. When adjusted for asthma severity, LAIV4 remained noninferior to IIV4. There were no significant differences in the frequency of asthma symptoms, change in PEFR, or childhood asthma control test/asthma control test scores in the 14 days postvaccination between LAIV4 and IIV4 recipients. Vaccine reactogenicity was similar between groups, although sore throat (P = .051) and myalgia (P <.001) were more common in the IIV4 group. CONCLUSIONS: LAIV4 was not associated with increased frequency of asthma exacerbations, an increase in asthma-related symptoms, or a decrease in PEFR compared with IIV4 among children aged 5 to 17 years with asthma.
引用
- Sokolow AG, Stallings AP, Kercsmar C, et al. Safety of Live Attenuated Influenza Vaccine in Children With Asthma. Pediatrics. 2022. PMID: 35342923. doi:10.1542/peds.2021-055432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。